İ. DOĞAN Et Al. , "Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors," JOURNAL OF DIGESTIVE DISEASES , vol.23, pp.493-499, 2022
DOĞAN, İ. Et Al. 2022. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. JOURNAL OF DIGESTIVE DISEASES , vol.23 , 493-499.
DOĞAN, İ., Tastekin, D., Karabulut, S., & Sakar, B., (2022). Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. JOURNAL OF DIGESTIVE DISEASES , vol.23, 493-499.
DOĞAN, İzzet Et Al. "Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors," JOURNAL OF DIGESTIVE DISEASES , vol.23, 493-499, 2022
DOĞAN, İzzet Et Al. "Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors." JOURNAL OF DIGESTIVE DISEASES , vol.23, pp.493-499, 2022
DOĞAN, İ. Et Al. (2022) . "Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors." JOURNAL OF DIGESTIVE DISEASES , vol.23, pp.493-499.
@article{article, author={İzzet DOĞAN Et Al. }, title={Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors}, journal={JOURNAL OF DIGESTIVE DISEASES}, year=2022, pages={493-499} }